Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huperzine A Injection for Postoperative Cognitive Dysfunction in Aneurysmal Subarachnoid Hemorrhage
NCT05560373Phase 4Not yet recruiting
- Sponsor
- Wanbangde Pharmaceutical Holding Group
- Start
- Dec 2026
- Primary completion
- Dec 2029
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of Huperzine A in Post-operative cognitive dysfunction (POCD), sponsored by Wanbangde Pharmaceutical Holding Group. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
Huperzine A
03
Conditions
Post-operative cognitive dysfunction (POCD)
Beyond the preview
Go deeper on NCT05560373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05560373.